Oncology Central

Cutting edge ‘digistain’ technology offers revolution in cancer diagnosis

A novel imaging technology, developed by researchers from Imperial College London (UK), could revolutionize how tumor biopsies are graded. The technology, termed ‘digistain’, was recently described in the journal Convergent Science Physical Oncology.

Currently, almost all cancers are diagnosed by excised biopsy specimens whereby the severity of the disease is judged by eye alone through the microscope. It is well known that different practitioners given the same biopsy will only agree on its grade about 70% of the time, resulting in an over treatment problem.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.